GW Pharmaceuticals

  • Ticker:NYSE:GWPH
  • Sector:Healthcare
  • Industry:Pharmaceutical
  • CEO:Justin Gover
  • Founded:1998
Categories:
About Us

Pioneers from the start, GW Pharmaceuticals (NASDAQGWPH) was founded in 1998 by Doctors Geoffrey Guy and Brian Whittle. That year, they obtained the necessary licenses to cultivate, possess and supply cannabis in order to carry out scientific research around the plant.

From there, the company went on to create Sativex in 2014, a cannabinoid drug designed as treatment for multiple sclerosis (MS) which was the first cannabis derivative to receive market approval in any country.

And in 2018, the company came out with Epidiolex, which remains the only cannabis drug currently approved by the US Food and Drug Administration. Epidiolex is used to treat epilepsy.

To date Over 12,000 patients have received Epidiolex prescriptions since launch, with 2019 Q2 net sales of $68.4M made from the product. That same quarter, the company reported a revenue of $72 million.

More From GW Pharmaceuticals...
GW Pharma's Epidiolex Makes Q1 Sales of $33.5 Million
GW Pharma to Issue 1.9M American Depositary Shares – Set to Raise $300 Million
GW Pharmaceuticals releases Q3 results
Investor Presentation

The latest update from the company

Click Here
Stay updated about
this company

Signup to get updates.

Management
Dr. Geoffrey Guy
Chairman & Founder
Dr. Geoffrey Guy is the founder of GW Pharmaceuticals, and has served as its Chairman since 1998. He is also the creator of Sativex and Epidiolex and continues to lead innovation and new product discovery. Guy has been actively involved in scientific innovation, medical research and global drug development for his entire career. Prior to his role at GW, Dr Guy served as Chairman and Chief Executive of Ethical Holdings plc, a NASDAQ-quoted drug delivery Company.
Justin Gover
CEO & Executive Director
Justin Gover has served as Chief Executive Officer of GW Pharmaceuticals since January 1999, shortly afer the Company was founded. He has 21 years’ experience in the pharmaceutical industry, and raised initial rounds of private capital for the company, following which he led its initial public offering on the AIM stock exchange in London in 2001, and more recently led GW’s initial public offering on Nasdaq in 2013.
Chris Tovey
Chief Operating Officer
Chris Tovey has served as Chief Operating Officer of GW Pharmaceuticals since October 2012. He has over 25 years experience in the pharmaceutical industry, and was previously employed at UCB Pharmaceuticals and GlaxoSmithKline plc, where he spent 18 years working in senior commercial roles in both the European and U.K. organisations. Most recently, Mr. Tovey acted as the Vice President of Global Marketing Operations, where he was responsible for worldwide marketing activities on a portfolio of UCB products generating over €2.0 billion in annual sales.